BEDMINSTER, N.J., and DUBLIN, Ireland, Feb. 4, 2014 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that industry veteran, Aaron Berg, has been promoted to Senior Vice President, Marketing and Sales.
With more than 25 years of industry experience, Mr. Berg has significant marketing and sales experience, including six years at Kos Pharmaceuticals where as Vice President of Marketing and Sales his contributions to the commercial success of Niaspan ® helped lead to the acquisition of Kos in 2006 by Abbott Laboratories for $3.6 billion. Before joining Kos Pharmaceuticals, Mr. Berg began his pharmaceutical industry career as a sales representative with Bristol-Myers Squibb followed by 10 years of increasing commercial responsibility at Schering-Plough before being recruited by GlaxoSmithKline to help build its then newly launched diabetes franchise. After Kos Pharmaceuticals, Mr. Berg's commercial and business development expertise in lipid therapy led Essentialis, a development-stage company focused on triglyceride management, to appoint Mr. Berg as President and CEO where he remained until he was recruited by Amarin at the end of 2012. Mr. Berg joined Amarin as Vice President, Marketing and Managed Care, which responsibilities he assumed from the time of launch of Vascepa ® in early 2013.
"On behalf of Amarin and its Board of Directors, it is with great pleasure that I announce the promotion of Aaron to this important expanded role," stated John F. Thero, President and Chief Executive Officer of Amarin. "Aaron's experience, leadership and dedication since joining Amarin have been crucial factors in establishing the sales focus, product messaging and managed care wins that position Vascepa for further growth. I have the utmost confidence in Aaron's ability to build on these efforts in leading Amarin's commercial team positively forward in its second year of Vascepa commercialization."